DE60143535D1 - Humane antikörper gegen cd40 - Google Patents

Humane antikörper gegen cd40

Info

Publication number: DE60143535D1
Authority: DE; Germany
Prior art keywords: antigen; antibody; cell; binding fragment; antagonist
Prior art date: 2000-10-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60143535T

Other languages

English (en)

Inventor

Keting Chu

Changyu Wang

Corrine Yoshihara

John J Donnelly

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis Vaccines and Diagnostics Inc

Original Assignee

Novartis Vaccines and Diagnostics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-02

Filing date

2001-10-02

Publication date

2011-01-05

2001-10-02 Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc

2011-01-05 Application granted granted Critical

2011-01-05 Publication of DE60143535D1 publication Critical patent/DE60143535D1/de

2021-10-03 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Hematology (AREA)
Genetics & Genomics (AREA)
Rheumatology (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pain & Pain Management (AREA)
Gastroenterology & Hepatology (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DE60143535T 2000-10-02 2001-10-02 Humane antikörper gegen cd40 Expired - Lifetime DE60143535D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23755600P	2000-10-02	2000-10-02
PCT/US2001/030857 WO2002028904A2 (en)	2000-10-02	2001-10-02	Human anti-cd40 antibodies

Publications (1)

Publication Number	Publication Date
DE60143535D1 true DE60143535D1 (de)	2011-01-05

Family

ID=22894238

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE60143535T Expired - Lifetime DE60143535D1 (de)	2000-10-02	2001-10-02	Humane antikörper gegen cd40
DE60119945T Expired - Lifetime DE60119945T2 (de)	2000-10-02	2001-10-02	VERFAHREN ZUR THERAPIE VON B-ZELLMALIGNITÄTEN UNTER VERWENDUNG VON ANTAGONISTISCHEN ANTI-CD40-Antikörpern

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DE60119945T Expired - Lifetime DE60119945T2 (de)	2000-10-02	2001-10-02	VERFAHREN ZUR THERAPIE VON B-ZELLMALIGNITÄTEN UNTER VERWENDUNG VON ANTAGONISTISCHEN ANTI-CD40-Antikörpern

Country Status (10)

Country	Link
US (5)	US7288252B2 (de)
EP (3)	EP1717251B1 (de)
JP (6)	JP4271440B2 (de)
AT (3)	ATE541860T1 (de)
AU (4)	AU2002211366A1 (de)
CA (2)	CA2424296A1 (de)
DE (2)	DE60143535D1 (de)
ES (1)	ES2357051T3 (de)
PT (1)	PT1326896E (de)
WO (4)	WO2002028481A2 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7063845B2 (en)	2000-04-28	2006-06-20	Gemini Science, Inc.	Human anti-CD40 antibodies
CA2424296A1 (en) *	2000-10-02	2002-04-11	Chiron Corporation	Human anti-cd40 antibodies
US7507724B2 (en) *	2001-01-16	2009-03-24	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
US7906492B2 (en)	2001-01-16	2011-03-15	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
EP2009027B1 (de)	2001-04-27	2014-05-21	Kyowa Hakko Kirin Co., Ltd.	Monoklonaler Antikörper gegen CD40
US20070098718A1 (en) *	2003-11-04	2007-05-03	Chiron	Methods of therapy for b cell-related cancers
JP4765037B2 (ja) *	2003-11-04	2011-09-07	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	慢性リンパ球性白血病の処置のためのアンタゴニスト抗ｃｄ４０モノクローナル抗体の使用
PL1684805T3 (pl) *	2003-11-04	2010-12-31	Novartis Vaccines & Diagnostics Inc	Sposoby leczenia szpiczaka mnogiego z zastosowaniem antagonistycznych monoklonalnych przeciwciał przeciwko CD40
US8277810B2 (en)	2003-11-04	2012-10-02	Novartis Vaccines & Diagnostics, Inc.	Antagonist anti-CD40 antibodies
WO2005044305A2 (en) *	2003-11-04	2005-05-19	Chiron Corporation	Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
EP1694360B1 (de)	2003-11-04	2010-08-04	Novartis Vaccines and Diagnostics, Inc.	Verwendung von antagonist-anti-cd40-antikörpern zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen und organtransplantat-abstossung
US20050136055A1 (en) *	2003-12-22	2005-06-23	Pfizer Inc	CD40 antibody formulation and methods
US20070292439A1 (en) *	2004-04-27	2007-12-20	Novartis Vaccines And Diagnostics, Inc.	Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
AU2006235695B2 (en)	2005-04-09	2011-10-13	Fusion Antibodies Limited	Cathepsin S antibody
EP1894012A2 (de) *	2005-05-18	2008-03-05	Novartis AG	Verfahren zur diagnose und behandlung von durch cd40-signalgebung vermittelten proliferativen störungen
CA2608750A1 (en) *	2005-05-18	2006-11-23	Novartis Ag	Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
US8926979B2 (en)	2005-11-01	2015-01-06	Novartis Ag	Treatment of cancer or pre-malignant conditions using anti-CD40 antibodies
US20090053221A1 (en) *	2006-01-17	2009-02-26	Cheung Nai-Kong V	Immune response enhancing glucan
US8323644B2 (en) *	2006-01-17	2012-12-04	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
NZ571757A (en)	2006-04-21	2012-01-12	Novartis Ag	Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
WO2007130493A2 (en) *	2006-05-03	2007-11-15	Regents Of The University Of Colorado	Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US20090074711A1 (en) *	2006-09-07	2009-03-19	University Of Southhampton	Human therapies using chimeric agonistic anti-human cd40 antibody
EP2708557A1 (de)	2007-05-30	2014-03-19	Xencor, Inc.	Verfahren und Zusammensetzungen zur Hemmung von CD32B-Expressionszellen
CA2705263A1 (en) *	2007-11-09	2009-05-14	Novartis Ag	Combination therapy with an antagonist anti-cd 40 antibody and cyclophosphamide, doxorubicin, vincristine and prednisone (chop) for treatment of b-cell malignancies
AU2009206506B2 (en) *	2008-01-23	2013-01-10	Xencor, Inc.	Optimized CD40 antibodies and methods of using the same
EP3219732A1 (de)	2009-03-10	2017-09-20	Baylor Research Institute	Auf antigenpräsentierende zellen gerichtete tumorimpfstoffe
ES2622228T3 (es)	2009-03-10	2017-07-06	Baylor Research Institute	Vacunas antivíricas dirigidas a células presentadoras de antígenos
CA2754862C (en)	2009-03-10	2019-04-02	Baylor Research Institute	Anti-cd40 antibodies and uses thereof
WO2011109280A1 (en)	2010-03-05	2011-09-09	Lerner Research Institute	Methods and compositions to treat immune-mediated disorders
ES2993140T3 (en)	2010-04-02	2024-12-23	Amunix Pharmaceuticals Inc	Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
AR083847A1 (es)	2010-11-15	2013-03-27	Novartis Ag	Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en)	2010-11-30	2012-06-07	Novartis Ag	Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
FI3556774T3 (fi)	2011-03-11	2024-03-15	Beth Israel Deaconess Medical Ct Inc	Anti-cd40-vasta-aineita ja niiden käyttötapoja
TW201300418A (zh)	2011-03-25	2013-01-01	Baylor Res Inst	用於抗ｃ型肝炎病毒免疫之組合物及方法
ES2664619T3 (es) *	2011-04-21	2018-04-20	Bristol-Myers Squibb Company	Polipéptidos de anticuerpos que antagonizan CD40
US9624310B2 (en)	2011-11-17	2017-04-18	Gundram Jung	Methods of using bi-specific antibodies for treating B-cell-mediated autoimmune diseases or auto-reactive B-cells
JP2016011258A (ja) *	2012-10-26	2016-01-21	株式会社ペルセウスプロテオミクス	抗ヒトｃｄ４０モノクローナル抗体及びその利用
US10590202B2 (en)	2012-11-19	2020-03-17	Baliopharm Ag	Recombinant bispecific antibody binding to CD20 and CD95
US10286058B2 (en)	2014-01-13	2019-05-14	Baylor Research Institute	Vaccines against HPV and HPV-related diseases
WO2015134988A1 (en)	2014-03-07	2015-09-11	Bristol-Myers Squibb Company	Method of using antibody polypeptides that antagonize cd40 to treat ibd
SG10201913099YA (en)	2014-10-29	2020-02-27	Seattle Genetics Inc	Dosage and administration of non-fucosylated anti-cd40 antibodies
JP6830437B2 (ja)	2014-12-10	2021-02-17	リージェンツオブザユニバーシティオブミネソタ	疾患を処置するための遺伝子改変された細胞、組織および臓器
PE20180193A1 (es)	2015-05-29	2018-01-26	Abbvie Inc	Anticuerpos anti-cd40 y sus usos
HUE056769T2 (hu)	2015-09-04	2022-03-28	Primatope Therapeutics Inc	Humanizált anti-CD40 antitestek és felhasználásuk
BR112018006360A2 (pt) *	2015-09-30	2018-10-09	Janssen Biotech Inc	anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
EP3468997B1 (de)	2016-06-08	2023-09-13	Xencor, Inc.	Behandlung von erkrankungen im zusammenhang mit igg4 mit anti-cd19-antikörpern mit kreuzbindung an cd32b
SG11201810509PA (en)	2016-06-20	2018-12-28	Kymab Ltd	Anti-pd-l1 antibodies
EP3484922A1 (de)	2016-07-14	2019-05-22	Genmab A/S	Multispezifische antikörper gegen cd40 und cd137
EP4252629A3 (de)	2016-12-07	2023-12-27	Biora Therapeutics, Inc.	Verfahren, vorrichtungen und systeme zur detektion des magen-darm-trakts
EP3600416B1 (de)	2017-03-30	2023-06-07	Biora Therapeutics, Inc.	Behandlung einer erkrankung des gastrointestinaltraktes mit einem immunmodulatorischen mittel, das mit einer einnehmbaren vorrichtung freigesetzt wird.
BR112019025048A2 (pt)	2017-06-01	2020-06-30	Jiangsu Hengrui Medicine Co., Ltd.	anticorpo anti-cd40, fragmento de ligação ao antígeno do mesmo, e uso médico dos mesmos
CN108503708B (zh) *	2017-09-01	2021-07-30	北京智仁美博生物科技有限公司	抗人cd47抗体及其用途
US10610585B2 (en)	2017-09-26	2020-04-07	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and compositions for treating and preventing HIV
US20210251994A1 (en)	2018-06-15	2021-08-19	Flagship Pioneering Innovations V, Inc.	Increasing immune activity through modulation of postcellular signaling factors
US20230041197A1 (en)	2018-06-20	2023-02-09	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease or condition in a tissue originating from the endoderm
WO2020070288A1 (en)	2018-10-05	2020-04-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and systems for controlling the agonistic properties of antibody variable domains by light
US20220249814A1 (en)	2018-11-19	2022-08-11	Progenity, Inc.	Methods and devices for treating a disease with biotherapeutics
TW202039558A (zh)	2018-11-30	2020-11-01	大陸商江蘇恆瑞醫藥股份有限公司	抗ｃｄ４０抗體、其抗原結合片段及其醫藥用途
CA3121291A1 (en)	2018-11-30	2020-06-04	Jiangsu Hengrui Medicine Co., Ltd.	Cd40 antibody pharmaceutical composition and use thereof
NL2022494B1 (en) *	2019-02-01	2020-08-19	Lava Therapeutics B V	Novel CD40-binding antibodies
JP2022519082A (ja) *	2019-02-01	2022-03-18	ラヴァ・セラピューティクス・ベー・フェー	新規ｃｄ４０結合抗体
MA55805A (fr)	2019-05-03	2022-03-09	Flagship Pioneering Innovations V Inc	Métodes de modulation de l'activité immunitaire
CA3163358A1 (en)	2019-12-03	2021-06-10	Evotec International Gmbh	Interferon-associated antigen binding proteins and uses thereof
EP4309722A3 (de)	2019-12-13	2024-08-07	Biora Therapeutics, Inc.	Einnehmbare vorrichtung zur abgabe eines therapeutischen mittels an den magen-darm-trakt
EP4076434A1 (de)	2019-12-17	2022-10-26	Flagship Pioneering Innovations V, Inc.	Kombination von antikrebstherapien mit induktoren der eisenabhängigen zellulären zerlegung
CN116096906A (zh)	2020-06-29	2023-05-09	旗舰创业创新五公司	工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
JP2024506831A (ja)	2021-01-28	2024-02-15	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	サイトカイン放出症候群を治療するための組成物及び方法
IL305681A (en)	2021-03-09	2023-11-01	Genmab As	Multispecific binding agents against cd40 and cd137 in therapy
JP2024512669A (ja)	2021-03-31	2024-03-19	フラグシップパイオニアリングイノベーションズブイ，インコーポレーテッド	タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
CA3219376A1 (en)	2021-05-07	2022-11-10	Redkik Oy	Risk probability assessment for cargo shipment operations and methods of use thereof
JP2024523514A (ja) *	2021-06-28	2024-06-28	江蘇恒瑞医薬股▲ふん▼有限公司	抗ｃｄ４０抗体、その抗原結合断片及び医薬用途
CA3224374A1 (en)	2021-06-29	2023-01-05	Flagship Pioneering Innovations V, Inc.	Immune cells engineered to promote thanotransmission and uses thereof
CA3225254A1 (en)	2021-07-13	2023-01-19	BioNTech SE	Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
CN120463762A (zh)	2021-08-26	2025-08-12	映恩生物科技(上海)有限公司	一种甾体化合物及其缀合物
US12234294B2 (en)	2021-11-05	2025-02-25	Kiniksa Pharmaceuticals, Gmbh	Pharmaceutical composition of a humanized anti-CD40 antibody
US20250249278A1 (en)	2022-04-14	2025-08-07	Institut National de la Santé et de la Recherche Médicale	Methods for controlling the tumor cell killing by light
WO2024077191A1 (en)	2022-10-05	2024-04-11	Flagship Pioneering Innovations V, Inc.	Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
JP2025541738A (ja)	2022-12-01	2025-12-23	ビオンテック・ソシエタス・エウロパエア	抗ｐｄ１ａｂと化学療法での併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性抗体
WO2024151687A1 (en)	2023-01-09	2024-07-18	Flagship Pioneering Innovations V, Inc.	Genetic switches and their use in treating cancer
WO2025184567A1 (en)	2024-03-01	2025-09-04	Regeneron Pharmaceuticals, Inc.	Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
US20250277048A1 (en)	2024-03-01	2025-09-04	Regeneron Pharmaceuticals, Inc.	The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US59427A (en) *		1866-11-06		Improvement in fences
US142358A (en) *		1873-09-02		Improvement in the purification of illuminating-gas
US4355023A (en)	1980-09-30	1982-10-19	The Massachusetts General Hospital	Antibody fragment compositions and process
NZ201918A (en)	1981-09-18	1987-04-30	Genentech Inc	N-terminal methionyl analogues of bovine growth hormone
US4689299A (en)	1982-09-30	1987-08-25	University Of Rochester	Human monoclonal antibodies against bacterial toxins
EP0138854B1 (de)	1983-03-08	1992-11-04	Chiron Mimotopes Pty. Ltd.	Antigen aktive aminosäuresequenzen
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
NZ212051A (en)	1984-05-18	1988-10-28	Univ Australian	Immune response suppression; certain epipolythio- dioxopiperazine derivatives and their preparation
US5068223A (en)	1985-09-09	1991-11-26	Board Of Regents, University Of Texas System	Hydrophobic peptide esters and amides
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5182368A (en)	1986-06-13	1993-01-26	Ledbetter Jeffrey A	Ligands and methods for augmenting B-cell proliferation
US4923872A (en)	1986-08-26	1990-05-08	Warner-Lambert Co.	Analogues of pyrrolo[3,2d]pyrimidin-4-ones
US4831175A (en)	1986-09-05	1989-05-16	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
ATE68347T1 (de) *	1987-01-17	1991-11-15	Asta Pharma Ag	Synergistische kombination von azelastin und theophyllin oder azelastin und beta-mimetika.
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5100899A (en)	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
EP0434879A1 (de)	1989-12-14	1991-07-03	Schering-Plough	Verfahren zur Herstellung von faktorabhÀ¤ngigen menschlichen B-Zellinien
WO1992000092A1 (en)	1990-07-02	1992-01-09	Bristol-Myers Squibb Company	Ligand for cd28 receptor on b cells and methods
AU661360B2 (en)	1991-10-25	1995-07-20	Immunex Corporation	Novel cytokine
CA2507749C (en)	1991-12-13	2010-08-24	Xoma Corporation	Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
IL104684A0 (en)	1992-02-14	1993-06-10	Bristol Myers Squibb Co	The cd40cr receptor and ligands therefor
WO1994001457A1 (en)	1992-07-07	1994-01-20	Fish Eleanor N	Interferon receptor binding peptides
US5397703A (en)	1992-07-09	1995-03-14	Cetus Oncology Corporation	Method for generation of antibodies to cell surface molecules
ATE339451T1 (de) *	1992-07-09	2006-10-15	Novartis Vaccines & Diagnostic	Antagonistische monoklonale antikörper gegen menschliches cd40
US5874082A (en)	1992-07-09	1999-02-23	Chiron Corporation	Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
WO1994004570A1 (en)	1992-08-21	1994-03-03	Schering Corporation	Cd40 ligand, anti cd40 antibodies, and soluble cd40
CA2115811A1 (en)	1993-02-17	1994-08-18	Claus Krebber	A method for in vivo selection of ligand-binding proteins
US5595721A (en)	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
CA2172376C (en)	1993-10-01	2008-11-18	William C. Fanslow, Iii	Antibodies to cd40
DK0751781T3 (da) *	1993-12-23	2004-08-09	Immunex Corp	Anvendelse af monoklonale antistoffer eller oplöselige oligomere ligander til fremstillingen af et medikament til forebyggelse eller behandling af neoplastiske sygdomme
AU2466895A (en) *	1995-04-28	1996-11-18	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US20020102208A1 (en)	1999-03-01	2002-08-01	Paul Chinn	Radiolabeling kit and binding assay
MY133346A (en)	1999-03-01	2007-11-30	Biogen Inc	Kit for radiolabeling ligands with yttrium-90
EP1173589A1 (de)	1999-04-16	2002-01-23	F. Hoffmann-La Roche Ag	Nukleotidensäure kodierend für cd40/cd40l chimerische polypeptiden , verfahren fur deren herstellung and anwendung davon
US6946129B1 (en)	1999-06-08	2005-09-20	Seattle Genetics, Inc.	Recombinant anti-CD40 antibody and uses thereof
ATE363290T1 (de) *	1999-10-04	2007-06-15	Novartis Vaccines & Diagnostic	Cd40 antagonist zur behandlung von psoriasis
US20020028178A1 (en) *	2000-07-12	2002-03-07	Nabil Hanna	Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU1590201A (en)	1999-11-09	2001-06-06	Chiron Corporation	Compositions and methods for treating autoimmune diseases and transplant rejections
US20030059427A1 (en)	2000-04-28	2003-03-27	Force Walker R.	Isolation and characterization of highly active anti-CD40 antibody
AU2001259215A1 (en) *	2000-04-28	2001-11-12	La Jolla Institute For Allergy And Immunology	Human anti-cd40 antibodies and methods of making and using same
US7063845B2 (en)	2000-04-28	2006-06-20	Gemini Science, Inc.	Human anti-CD40 antibodies
CA2424296A1 (en)	2000-10-02	2002-04-11	Chiron Corporation	Human anti-cd40 antibodies

2001
- 2001-10-02 CA CA002424296A patent/CA2424296A1/en not_active Abandoned
- 2001-10-02 DE DE60143535T patent/DE60143535D1/de not_active Expired - Lifetime
- 2001-10-02 AT AT06005656T patent/ATE541860T1/de active
- 2001-10-02 AU AU2002211366A patent/AU2002211366A1/en not_active Abandoned
- 2001-10-02 EP EP06005656A patent/EP1717251B1/de not_active Expired - Lifetime
- 2001-10-02 JP JP2002532486A patent/JP4271440B2/ja not_active Expired - Lifetime
- 2001-10-02 AT AT01977428T patent/ATE327004T1/de not_active IP Right Cessation
- 2001-10-02 EP EP01977428A patent/EP1322383B9/de not_active Expired - Lifetime
- 2001-10-02 AU AU2001296547A patent/AU2001296547A1/en not_active Abandoned
- 2001-10-02 ES ES01979395T patent/ES2357051T3/es not_active Expired - Lifetime
- 2001-10-02 AU AU2001296507A patent/AU2001296507A1/en not_active Abandoned
- 2001-10-02 WO PCT/US2001/030963 patent/WO2002028481A2/en not_active Ceased
- 2001-10-02 US US10/380,223 patent/US7288252B2/en not_active Expired - Fee Related
- 2001-10-02 EP EP01979395A patent/EP1326896B1/de not_active Expired - Lifetime
- 2001-10-02 AU AU2001296545A patent/AU2001296545A1/en not_active Abandoned
- 2001-10-02 JP JP2002532304A patent/JP4202127B2/ja not_active Expired - Fee Related
- 2001-10-02 WO PCT/US2001/030857 patent/WO2002028904A2/en not_active Ceased
- 2001-10-02 DE DE60119945T patent/DE60119945T2/de not_active Expired - Lifetime
- 2001-10-02 CA CA002424749A patent/CA2424749A1/en not_active Abandoned
- 2001-10-02 PT PT01979395T patent/PT1326896E/pt unknown
- 2001-10-02 WO PCT/US2001/030859 patent/WO2002028905A2/en not_active Ceased
- 2001-10-02 AT AT01979395T patent/ATE489403T1/de active
- 2001-10-02 WO PCT/US2001/030961 patent/WO2002028480A2/en not_active Ceased
2007
- 2007-08-31 US US11/849,107 patent/US7445780B2/en not_active Expired - Fee Related
- 2007-11-19 JP JP2007299859A patent/JP2008156339A/ja active Pending
- 2007-11-26 JP JP2007305086A patent/JP2008074870A/ja active Pending
2008
- 2008-08-28 JP JP2008220544A patent/JP4838831B2/ja not_active Expired - Fee Related
- 2008-10-06 US US12/246,029 patent/US7611708B2/en not_active Expired - Fee Related
2009
- 2009-06-16 JP JP2009143746A patent/JP2009201523A/ja active Pending
- 2009-09-28 US US12/568,373 patent/US7820170B2/en not_active Expired - Fee Related
2010
- 2010-09-27 US US12/891,415 patent/US8088383B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ATE489403T1 (de)	2010-12-15
US7445780B2 (en)	2008-11-04
AU2001296507A1 (en)	2002-04-15
US20110033456A1 (en)	2011-02-10
JP2009019046A (ja)	2009-01-29
US7820170B2 (en)	2010-10-26
EP1326896B1 (de)	2010-11-24
US20090081242A1 (en)	2009-03-26
WO2002028481A2 (en)	2002-04-11
AU2001296545A1 (en)	2002-04-15
US8088383B2 (en)	2012-01-03
AU2002211366A1 (en)	2002-04-15
JP2008156339A (ja)	2008-07-10
JP2004510752A (ja)	2004-04-08
EP1322383B9 (de)	2006-09-06
EP1326896A2 (de)	2003-07-16
ATE541860T1 (de)	2012-02-15
WO2002028905A2 (en)	2002-04-11
US20040109857A1 (en)	2004-06-10
AU2001296547A1 (en)	2002-04-15
US20100172912A1 (en)	2010-07-08
EP1322383A2 (de)	2003-07-02
DE60119945D1 (de)	2006-06-29
JP2008074870A (ja)	2008-04-03
WO2002028904A2 (en)	2002-04-11
JP2009201523A (ja)	2009-09-10
EP1717251A3 (de)	2007-11-07
WO2002028480A2 (en)	2002-04-11
EP1717251A2 (de)	2006-11-02
WO2002028481A3 (en)	2003-03-06
ES2357051T3 (es)	2011-04-15
WO2002028480A3 (en)	2002-07-11
US7288252B2 (en)	2007-10-30
JP4271440B2 (ja)	2009-06-03
CA2424749A1 (en)	2002-04-11
WO2002028904A3 (en)	2003-02-06
CA2424296A1 (en)	2002-04-11
WO2002028905A3 (en)	2002-06-20
US20080075727A1 (en)	2008-03-27
JP4202127B2 (ja)	2008-12-24
EP1322383B1 (de)	2006-05-24
PT1326896E (pt)	2011-03-03
US7611708B2 (en)	2009-11-03
JP4838831B2 (ja)	2011-12-14
ATE327004T1 (de)	2006-06-15
WO2002028481A9 (en)	2003-07-03
EP1717251B1 (de)	2012-01-18
DE60119945T2 (de)	2007-01-18
JP2004517611A (ja)	2004-06-17

Publication	Publication Date	Title
ATE489403T1 (de)	2010-12-15	Humane antikörper gegen cd40
CY1111011T1 (el)	2015-06-11	Χρηση των anti-cd40 μονοκλωνικων αντισωματων για την θεραπευτικη αγωγη πολλαπλου μυελωματος
SG148143A1 (en)	2008-12-31	Antagonist anti-cd40 monoclonal antibodies and methods for their use
CY1110874T1 (el)	2015-06-10	Μεθοδοι θεραπειας για συμπαγεις ογκους που εκφραζουν to cd40 αντιγονο κυτταρικης επιφανειας
CY1118429T1 (el)	2017-06-28	Αντισωμα συνδεσης αλφα4βητα7 ιντεγκρινης και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
CY1112473T1 (el)	2015-12-09	Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
EA201300022A1 (ru)	2014-01-30	Терапевтическое человеческое моноклональное антитело против il-1r1
DE69709632D1 (de)	2002-02-28	Humanisierte monoklonale anti-cd40 antikörper und fragmente zur hemmung der b-zellaktivierung
DK2371391T3 (da)	2014-11-03	Terapeutisk anvendelse af anti-CS1-antistoffer
NZ592039A (en)	2013-03-28	Combination therapy for the treatment of ocular neovascular disorders
NO20015122L (no)	2001-12-21	Behandling av fibrose ved anvendelse av en antagonist for integrin <alfa>-4-subenheten
DE60217698D1 (de)	2007-03-08	Behandlung chronischer gelenkentzündung unter verwendung eines antikörpers gegen das cd3 antigenkomplex
TR200103432T2 (tr)	2002-10-21	Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
JP2004500325A5 (de)	2007-05-24
WO2004019886A3 (en)	2004-09-10	Methods for up-regulating antigen expression in tumors
BR0315140A (pt)	2005-08-16	Combinação, composição farmacêutica, método de tratamento do câncer em um animal de sangue quente, e, uso de uma combinação
RU2002103808A (ru)	2003-11-27	Способ лечения болевого синдрома у онкологических больных
NZ329403A (en)	2000-09-29	Treatment of B-cell lymphomas using a CD40 binding protein that inhibits the binding of CD40 to CD40L

Legal Events

Date	Code	Title	Description
2011-06-16	8328	Change in the person/name/address of the agent	Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN